Chimerix, Inc. - CMRX STOCK NEWS

Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.

Chimerix, Inc. (NASDAQ: CMRX) is a pioneering biopharmaceutical company focused on the development of innovative antiviral therapeutics. Led by a team of experienced professionals, Chimerix aims to enhance the quality of life for patients across diverse medical fields, including transplant, oncology, acute care, and global health.

Chimerix leverages its proprietary lipid technology, resulting in two promising clinical-stage compounds: CMX001 and CMX157. These compounds have shown potential for improved activity, bioavailability, and safety over existing drugs. The lead compound, CMX001, is a broad-spectrum antiviral that combats double-stranded DNA (dsDNA) viruses, such as cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus, and variola (smallpox). CMX001 has completed Phase 2 development for CMV prophylaxis and is currently in Phase 2 trials for adenovirus treatment in hematopoietic stem cell transplant (HSCT) recipients.

Chimerix’s portfolio also includes ONC201, an oral, first-in-class small molecule imipridone targeting H3 K27M-mutant gliomas. The Phase 3 ACTION trial for ONC201 is a major focus, enrolling patients at over 130 sites in 13 countries. This study aims to report interim overall survival data by early 2025. Additionally, Chimerix's second-generation compound, ONC206, is undergoing Phase I dose escalation trials, demonstrating anti-cancer activity in both CNS and non-CNS tumors.

Financially, Chimerix maintains a robust balance sheet with significant capital to fund ongoing operations, reflecting sound fiscal management. The company reported a net loss of $18.6 million for Q2 2023 but continues to advance its research and development initiatives.

Chimerix’s mission is to develop medications that significantly improve and extend the lives of patients battling severe diseases. With ongoing clinical trials, strategic financial planning, and a dedicated team, Chimerix is poised to make substantial contributions to global health.

12/04/2023 07:00 AM

News

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) announced the promotion of Michelle LaSpaluto to Chief Financial Officer, effective December 1, 2023. LaSpaluto, with more than 25 years of financial experience, will lead the company into its next growth phase. She has been a proven leader within the company and has played a pivotal role in various areas core to the CFO role, including capital raising, accounting, investor relations, internal controls, and business development transactions. Her deep familiarity with the company's operating structure and programs will enable a smooth transition to the expanded responsibility. LaSpaluto's promotion reflects the company's commitment to advancing its imipridone pipeline and building Chimerix into a leading oncology company.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.97%

Tags

11/24/2023 07:00 AM

News

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Chimerix (CMRX) granted 150,000 non-qualified stock options to a new employee, with an exercise price of $1.00 per share. The stock option has a 10-year term, vesting over four years. Chimerix is a biopharmaceutical company focused on developing medicines, with its most advanced program, ONC201, in development for H3 K27M-mutant glioma.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.04%

Tags

11/16/2023 07:00 AM

News

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) appoints Thomas Riga as Chief Operating and Commercial Officer, leveraging his 25 years of oncology commercialization and business development experience to advance ONC201 toward commercialization. Riga's previous leadership roles at Spectrum Pharmaceuticals, Dendreon, Amgen, and Eli Lilly and Company, coupled with his B.S. in Biology and Chemistry, position him to drive Chimerix's growth and bring potentially life-altering drugs to patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.17%

Tags

11/02/2023 07:00 AM

News

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Rhea-AI Summary

Chimerix, a biopharmaceutical company, reported financial results for Q3 2023 and provided an operational update. The Phase 3 ACTION study for ONC201 is ongoing with 113 sites activated across 12 countries. Interim survival and PFS data are on track to report in 2025. The company is actively recruiting for ONC206 dose escalation studies, with enrollment on track to complete in the first half of 2024. Chimerix reported a net loss of $24.0 million for Q3 2023. Research and development expenses increased to $17.4 million, while general and administrative expenses increased to $9.3 million. The company expects to end the year with over $200 million in cash and cash equivalents.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.08%

Tags

10/26/2023 07:00 AM

News

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

Rhea-AI Summary

Chimerix to host conference call and webcast to report Q3 2023 financial results and provide business overview

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/05/2023 07:00 AM

News

Chimerix to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Chimerix to participate in investor conferences

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.85%

Tags

08/16/2023 10:05 AM

News

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Rhea-AI Summary

Chimerix announced the publication of data supporting ONC201 as a treatment for H3 K27M-mutant diffuse midline gliomas. Patients treated with ONC201 showed a median overall survival of 21.7 months compared to 12 months in historical controls. The treatment disrupts key metabolic and epigenetic pathways.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.03%

Tags

08/03/2023 07:00 AM

News

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Rhea-AI Summary

Chimerix (CMRX) is conducting a Phase 3 ACTION study across 11 countries with 77 sites activated, expecting the first interim overall survival analysis in early 2025. They also anticipate completing ONC206 dose escalation in the first half of 2024 with $233 million available for operations as of June 30, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.69%

Tags

07/27/2023 07:00 AM

News

Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) to Report Q2 2023 Financial Results and Business Overview on August 3, 2023

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.56%

Tags

06/27/2023 04:05 PM

News

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.59%

Tags

FAQ

What is the current stock price of Chimerix (CMRX)?

The current stock price of Chimerix (CMRX) is $3.34 as of December 24, 2024.

What is the market cap of Chimerix (CMRX)?

The market cap of Chimerix (CMRX) is approximately 300.4M.

What does Chimerix, Inc. do?

Chimerix, Inc. is a biopharmaceutical company specializing in the development of novel antiviral therapeutics aimed at improving quality of life for patients in various medical fields including transplant, oncology, acute care, and global health.

What are Chimerix's leading compounds?

Chimerix's leading compounds include CMX001, a broad-spectrum antiviral targeting dsDNA viruses, and ONC201, a first-in-class small molecule imipridone for treating H3 K27M-mutant gliomas.

What stages are Chimerix's clinical trials in?

CMX001 has completed Phase 2 trials for CMV prophylaxis and is in Phase 2 for adenovirus treatment in HSCT recipients. ONC201 is in a Phase 3 ACTION trial for H3 K27M-mutant gliomas, and ONC206 is in Phase I dose escalation trials.

How is Chimerix financially positioned?

Chimerix maintains a strong balance sheet with significant capital to support ongoing operations. The company reported a net loss of $18.6 million for the second quarter of 2023.

What is the significance of the ONC201 Phase 3 ACTION trial?

The ONC201 Phase 3 ACTION trial is critical as it aims to provide interim overall survival data by early 2025, potentially validating ONC201 as a major therapeutic advance for treating H3 K27M-mutant gliomas.

What kind of partnerships does Chimerix have?

Chimerix collaborates with various research institutions and regulatory bodies worldwide to advance its clinical trials and research initiatives, particularly in neuro-oncology and antiviral therapeutics.

Where is Chimerix based?

Chimerix, Inc. is based in Durham, North Carolina, USA.

How does Chimerix generate revenue?

Chimerix generates revenue through non-refundable upfront fees, royalties, milestone payments from license agreements, and royalty revenue from sales of products like TEMBEXA made by partners like Emergent.

What is unique about Chimerix’s lipid technology?

Chimerix’s proprietary lipid technology enhances the activity, bioavailability, and safety of its compounds, potentially offering superior therapeutic benefits compared to currently approved drugs.